As the biosynthesis of MVP requires the activation and translocation of an acid sphingomyelinase (aSMase), our studies demonstrated that an aSMase-specific inhibitor, imipramine blocks targeted therapy-induced MVP release in NSCLC cells [28]. The gene discussed is SMPD1; the disease is non-small cell lung carcinoma.